Prognostic effect of epidermal growth factor receptor variant III in glioblastoma

HONG Jiakang; LI Xin; WANG Jianzhen

doi:10.13919/j.issn.2095-6274.2016.06.004

Abstract：Objective To investigate the influence of epidermal growth factor receptor variant Ⅲ (EGFRvⅢ) expression on the prognosis of patients with glioblastoma.Methods A total of 98 patients with glioblastoma were enrolled into this study from January 2012 to December 2015. The expression levels of EGFRv Ⅲ were detected by immunohistochemistry and analyzed their association with clinical parameters such as gender, age, tumor size, growth site and Karnofsky Performance Scale (KPS), etc.Results (1) The positive rate of EGFRv Ⅲ was 38.8% in 98 cases of patients but 0% in the normal. (2) Single factor analysis showed that age, KPS were statistically significantly different between EGFRv Ⅲ positive and negative groups (χ2=7.018,P=0.008;χ2=12.101,P=0.001). (3) Survival analysis results showed that median survival time was 13 months (95%CI, 8.99-17.01) in EGFRv Ⅲ negative group and 12 months (95%CI, 9.81-14.18) in EGFRv Ⅲ positive group; the median total survival time over 12 months was 22 months (95%CI, 16.91-27.09) in EGFRv Ⅲ negative group and 16 months (95%CI, 14.04-17.95) in EGFRv Ⅲ positive group; the median total survival time was 10 months (95%CI,6.73-13.27) in patients over 60 years old and 15 months (95%CI, 11.90-18.10) in patients under 60 years old. (4) Cox multiple factors analysis showed that KPS and positive expression of EGFRv Ⅲ were independent correlative factor of disease prognosis.Conclusions Positive expression of EGFRv Ⅲ, age and KPS are the risk factors influencing the prognosis of patients with glioblastoma.